CN102869385A - 针对组织因子途径抑制物的适体和其作为出血病症治疗剂的用途 - Google Patents

针对组织因子途径抑制物的适体和其作为出血病症治疗剂的用途 Download PDF

Info

Publication number
CN102869385A
CN102869385A CN2010800457286A CN201080045728A CN102869385A CN 102869385 A CN102869385 A CN 102869385A CN 2010800457286 A CN2010800457286 A CN 2010800457286A CN 201080045728 A CN201080045728 A CN 201080045728A CN 102869385 A CN102869385 A CN 102869385A
Authority
CN
China
Prior art keywords
amino acid
aptamer
tfpi
acid residues
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800457286A
Other languages
English (en)
Chinese (zh)
Inventor
R·G·肖布
K·麦金尼斯
J·纳尔逊
R·真加
E·沃特斯
J·C·库尔茨
J·L·迪耶内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN102869385A publication Critical patent/CN102869385A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN2010800457286A 2009-08-18 2010-08-17 针对组织因子途径抑制物的适体和其作为出血病症治疗剂的用途 Pending CN102869385A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US23493909P 2009-08-18 2009-08-18
US61/234,939 2009-08-18
US35337410P 2010-06-10 2010-06-10
US61/353,374 2010-06-10
US36636210P 2010-07-21 2010-07-21
US61/366,362 2010-07-21
US36776610P 2010-07-26 2010-07-26
US61/367,766 2010-07-26
PCT/US2010/045797 WO2011022427A1 (en) 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Publications (1)

Publication Number Publication Date
CN102869385A true CN102869385A (zh) 2013-01-09

Family

ID=43607310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800457286A Pending CN102869385A (zh) 2009-08-18 2010-08-17 针对组织因子途径抑制物的适体和其作为出血病症治疗剂的用途

Country Status (17)

Country Link
US (1) US8252913B2 (enExample)
EP (1) EP2467167B1 (enExample)
JP (1) JP2013502218A (enExample)
KR (1) KR20120061086A (enExample)
CN (1) CN102869385A (enExample)
AU (1) AU2010284329B2 (enExample)
BR (1) BR112012003806A2 (enExample)
CA (1) CA2770762A1 (enExample)
CO (1) CO6531414A2 (enExample)
ES (1) ES2655589T3 (enExample)
IL (1) IL218048A0 (enExample)
IN (1) IN2012DN01984A (enExample)
MX (1) MX2012002133A (enExample)
NZ (1) NZ598557A (enExample)
RU (1) RU2012110221A (enExample)
SG (1) SG178408A1 (enExample)
WO (1) WO2011022427A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138159A (zh) * 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
CN115792231A (zh) * 2022-11-04 2023-03-14 山东大学 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
CA2745317C (en) 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
EP2673364A1 (en) * 2011-02-11 2013-12-18 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CA2837503C (en) 2011-06-08 2018-01-02 Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej Sequence-specific engineered ribonuclease h and the method for determining the sequence preference of dna-rna hybrid binding proteins
AU2013235567A1 (en) * 2012-03-22 2014-10-09 Baxalta GmbH Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
EP3036542B1 (en) * 2013-06-21 2021-02-17 Imigene Inc. A method for assaying a blood sample obtained from a subject
EP3022228B1 (en) 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US9695424B2 (en) 2013-09-09 2017-07-04 Somalogic, Inc. PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
US11181534B2 (en) 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
JP6841430B2 (ja) * 2015-12-04 2021-03-10 全薬工業株式会社 血中滞留性を改善した抗ｉｌ−１７アプタマー
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US6410278B1 (en) * 1998-11-09 2002-06-25 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
PT1009413E (pt) 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
EP1919499A2 (en) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US6410278B1 (en) * 1998-11-09 2002-06-25 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BATES ET AL.,: "The status of new antiboagulants", 《BRITISH JOURNAL OF HAEMATOLOGY》, vol. 123, no. 1, 31 July 2006 (2006-07-31), pages 3 - 19 *
BROZE ET AL.,: "Tissue factor pathway inhibitor and the revised theory of coagulation", 《ANNUAL REVIEW OF MEDICINE》, vol. 46, 28 February 1995 (1995-02-28), pages 103 - 112, XP008154088 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138159A (zh) * 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
CN115792231A (zh) * 2022-11-04 2023-03-14 山东大学 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器

Also Published As

Publication number Publication date
CA2770762A1 (en) 2011-02-24
EP2467167A4 (en) 2013-12-25
CO6531414A2 (es) 2012-09-28
AU2010284329B2 (en) 2015-04-16
NZ598557A (en) 2013-08-30
EP2467167B1 (en) 2017-08-16
ES2655589T3 (es) 2018-02-20
WO2011022427A1 (en) 2011-02-24
MX2012002133A (es) 2013-02-15
US20110098345A1 (en) 2011-04-28
BR112012003806A2 (pt) 2016-11-16
SG178408A1 (en) 2012-03-29
KR20120061086A (ko) 2012-06-12
AU2010284329A1 (en) 2012-03-29
EP2467167A1 (en) 2012-06-27
RU2012110221A (ru) 2013-09-27
IN2012DN01984A (enExample) 2015-07-24
US8252913B2 (en) 2012-08-28
JP2013502218A (ja) 2013-01-24
IL218048A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
EP2467167B1 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8598327B2 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
ES2429442T3 (es) Aptámeros terapéuticos útiles en el tratamiento de trastornos relacionados con complemento
US7998940B2 (en) Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics
US7589073B2 (en) Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CN101155822B (zh) 用于治疗补体-相关失调的适体治疗
US20120149764A1 (en) Aptamers that bind thrombin with high affinity
US7566701B2 (en) Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP6002691B2 (ja) 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
AU2022202115A1 (en) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
HK1171959B (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
HK1171959A (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
AU2016204713B2 (en) Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
HK1256789B (en) Aptamer therapeutics useful in the treatment of complement-related disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130109